argenx NV ADR (ARGX)vsImpact BioMedical, Inc. (IBO)
ARGX
argenx NV ADR
$897.85
+0.68%
HEALTHCARE · Cap: $54.94B
IBO
Impact BioMedical, Inc.
$3.87
-3.01%
HEALTHCARE · Cap: $30.76M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 16901240% more annual revenue ($5.92B vs $35,000). IBO leads profitability with a 2260.0% profit margin vs 31.7%. IBO trades at a lower P/E of 0.3x. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
IBO
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.5%
Fair Value
$2566.94
Current Price
$897.85
$1669.09 discount
Intrinsic value data unavailable for IBO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Keeps 2260 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 166.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -112.2% — below average capital efficiency
Revenue declined 57.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bull Case : IBO
The strongest argument for IBO centers on P/E Ratio, Profit Margin. Profitability is solid with margins at 2260.0% and operating margin at -23400.0%.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : IBO
The primary concerns for IBO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ARGX profiles as a growth stock while IBO is a declining play — different risk/reward profiles.
IBO carries more volatility with a beta of 2.73 — expect wider price swings.
ARGX is growing revenue faster at 52.1% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 37/100), backed by strong 31.7% margins and 52.1% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Impact BioMedical, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Impact BioMedical, Inc. is an innovative biotechnology company focused on developing groundbreaking therapeutics and technologies to address critical healthcare challenges. Utilizing advanced research methodologies, the firm aims to improve patient outcomes and overall quality of life. With a robust intellectual property portfolio and an emphasis on scientific rigor, Impact BioMedical is well-positioned for growth in the evolving healthcare market. Its extensive product pipeline and strategic collaborations offer attractive investment opportunities for institutional investors interested in the accelerating biopharmaceutical sector.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?